Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma

✍ Scribed by Turner, Joel; Rhee, Juong G.; Fabian, Dagmar F.; Lefor, Alan T.

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 133 KB
• Volume: 66
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199709)66:1<39::aid-jso8>3.0.co;2-o

✦ Synopsis

Background and objectives:

Icam-1 is essential for lymphocyte-endothelial cell interactions. we have demonstrated that increased expression of icam-1 in tumors results in an enhanced response to adoptive immunotherapy. we undertook this study to determine whether increased expression of icam-1 results in increased lymphocyte adhesion in vivo.

Methods:

Parental mca-105 tumor cells were cotransfected with icam-1 and the neor plasmid. a neomycin resistant clone (cl149) was selected and increased expression of icam-1 confirmed by facs analysis. tumor fragments (mca-105 or cl149) were placed in a dorsal skin-fold chamber on day 0 in c57bl/6 mice. lymphocytes were fluorescently labeled using 0.5% acridine orange and activity recorded on videotape at 700x magnification. lymphocyte activity was quantitated over 30 second intervals in postcapillary venules as either passing or rolling/sticking (r/s). the % r/s was calculated for each category and evaluated using chi 2 analysis.

Results:

Whereas 38% of lymphocytes were classified as r/s in normal tissue, 32% were classified as r/s (p > .05) in the mca-105 tumor. however, in the icam-1 transfected cl149, there was significantly greater r/s at 53% (p < .05).

Conclusions:

These data demonstrate increased lymphocyte adhesion in tumors with enhanced expression of icam-1 by direct in vivo observations and may partially explain the salutary effect of increased icam-1 expression on adoptive immunotherapy. this suggests the possible application of adhesion molecule expression in the cellular therapy of cancer.